Zevra Therapeutics, Inc.

NASDAQ:ZVRA

Biotechnology

Healthcare
$9.28 +2.44%

+$0.31 today

Market cap
$552.20M
Beta
0.89
P/E (TTM)
6.1
EPS (TTM)
$2.13
52W Low $7.16High $14.27

Volume 0.62M

Average 1.43M

ZVRA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Zevra Therapeutics, Inc.NASDAQ: ZVRA

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin holds steady near 93.7%

Gross margin was 93.7% in Q1 FY2026, up 0.3 pp from a year earlier. On a trailing-twelve-month basis it was 85.5%, up 6.7 pp year over year. Over 3 fiscal years it narrowed by 13.3 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
93.7%-1.8 pp QoQ
Last fiscal yearDec 2025
84.5%+15.9 pp YoY
LTMMar 2026
85.5%+6.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+0.3 pp——
1 year+15.9 pp——
3 years-13.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
84.5%
Year-over-year change
+15.9pp

Gross Margin vs competitors

How ZVRA compares with its peers on the latest reported figures

  • ZVRA's LTM Mar 2026 gross margin of 85.5% is the 3rd highest of the 6 companies compared; the peer median is 82.9%.
  • Its year-over-year change of +6.7 pp is the highest of 5, against a peer median of -1.9 pp.
  • Over three fiscal years its change of -13.3 pp compares with a peer median of +2.7 pp.
ZVRA Competitors Peer median
Gross Margin for ZVRA and competitors
Company Period LTM level YoY 3-year change
NBIXNeurocrine Biosciences, Inc.LTM Sep 202697.8% -0.6 pp-0.3 pp
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 202688.1% -0.5 pp+2.7 pp
ZVRAZevra Therapeutics, Inc.LTM Mar 202685.5% +6.7 pp-13.3 pp
ALKSAlkermes plcLTM Sep 202682.9% -3.2 pp+6.3 pp
XENEXenon Pharmaceuticals Inc.FY202566.1% —-33.9 pp
JAZZJazz Pharmaceuticals plcLTM Sep 202664.2% -21.2 pp+3.0 pp
PRAXPraxis Precision Medicines, Inc.FY2025— ——
GHRSGH Research PLCFY2025— ——
ANROAlto Neuroscience, Inc.FY2025— ——
MPLTMapLight Therapeutics, Inc.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding ZVRA) 82.9%-1.9 pp+2.7 pp

Competitors are the stored peer set for ZVRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue28.65M10.16M27.46M23.61M106.47M
Cost of Revenue2.06M222K2.95M7.42M16.48M
Gross Profit26.59M9.94M24.52M16.2M89.99M
Gross Margin92.8%97.8%89.3%68.6%84.5%
Research & Development10.16M19.8M39.81M42.1M12.74M
Selling, General & Admin8.7M15.04M35.09M54.87M77.62M
Operating Expenses18.86M52.5M74.12M103.2M94.22M
Depreciation & Amortization257K944K1.01M6.39M4.05M
EBITDA(7.89M)(25.53M)(43.54M)(76.4M)98.71M
EBITDA Margin-27.5%-251.2%-158.6%-323.6%92.7%
Operating Income7.73M(42.57M)(49.6M)(87M)(4.23M)
Operating Margin27.0%-418.9%-180.6%-368.5%-4.0%
Interest Income261K1.51M4.54M2.18M6.95M
Interest Expense376K335K1.5M7.35M7.98M
Other Income / Expenses(16.25M)15.76M3.56M(3.14M)90.91M
Income Before Tax(8.52M)(26.81M)(46.05M)(90.14M)86.68M
Pre-Tax Margin-29.7%-263.8%-167.7%-381.8%81.4%
Income Tax Expense34K(33K)015.37M3.45M
Net Income(8.56M)(26.77M)(46.05M)(105.51M)83.23M
Net Margin-29.9%-263.5%-167.7%-446.9%78.2%
EPS (Basic)(2.11)(0.78)(1.30)(2.28)1.40
EPS (Diluted)(2.11)(0.78)(1.30)(2.28)1.35
Weighted Avg Shares29.77M34.49M35.45M46.25M55.31M
Weighted Avg Shares (Diluted)29.77M34.49M35.45M46.25M57.26M

Zevra Therapeutics, Inc.

NASDAQ:ZVRA

Intrinsic Alpha fair value

Locked

Current Price

$9.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.